Legendary Biotech announced that the European Commission (EC) has approved cilta-cel (cilta-cel, trade name Carvykti) for the treatment of adult patients with recurrent and refractory multiple myeloma. These patients have received at least first-line treatment (including a proteasome inhibitor and an immunomodulator), progressed in the last treatment and became resistant to lenalidomide. Sidakiolenol is a CAR-T therapy targeting B-cell maturation antigen (BCMA). In December 2017, Johnson & Johnson Innovative Medicine (Johnson & Johnson Innovative Medicine), a subsidiary of Johnson & Johnson (Johnson & Johnson), signed an exclusive global license and cooperation agreement with Legendary Biotech to develop and commercialize Sidakion.
强生(JNJ.US)&传奇生物CAR-T疗法再获欧盟批准
Johnson & Johnson (JNJ.US) & Legendary Biotech's CAR-T Therapy Receives EU Approval Again
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.